RxCelerate and Constructive Bio Announce Partnership to Advance Next-Generation Therapeutics
Cambridge, UK, 19th November 2025, 9am GMT
Combining Constructive Bio’s pioneering programmable biology platform with RxCelerate’s expert drug design and development capabilities to drive innovation in engineered biologics for challenging diseases.
Cambridge, UK – 19 November 2025 – Constructive Bio and RxCelerate have formed a strategic partnership to develop novel biologic therapeutic candidates targeting multiple disease indications, including liver fibrosis and other cardiometabolic diseases.
The collaboration brings together RxCelerate’s integrated drug discovery and development expertise with Constructive Bio’s proprietary programmable biology platform. Built on the pillars of synthetic genomics and engineered translation, Constructive Bio’s platform enables the biological incorporation of non-canonical amino acids (ncAAs) into peptide, protein and biologic therapies.
By expanding the chemical diversity of proteins, Constructive Bio’s technology opens new avenues for designing biologics with enhanced properties and therapeutic potential. Under the agreement, RxCelerate will design and deliver comprehensive drug discovery programmes, leveraging Constructive Bio’s proprietary platform, to demonstrate how programmable biology can transform biologic drug development.
By combining their expertise, RxCelerate and Constructive Bio are advancing a new generation of biologics designed to address complex diseases with limited treatment options.
“This partnership exemplifies how combining complementary strengths can accelerate innovation” said Dr Jill Reckless, CEO at RxCelerate. “Together, we aim to unlock new possibilities for next-generation therapeutics, demonstrating the full potential of Constructive Bio’s platform to create differentiated biologics that deliver meaningful benefits for patients.”
Dr Ola Wlodek, CEO at Constructive Bio said: “This collaboration demonstrates how rewriting life’s code can redefine what is possible in drug discovery – enabling entirely new classes of biologics for the world’s most challenging diseases with powerful new-to-nature chemistries. RxCelerate’s deep expertise and agile development model make them an ideal partner for us.”
Dr Jon Heal, Executive Vice President of ProsaRx at RxCelerate, said: “This collaboration brings together RxCelerate’s full suite of in-house capabilities, from in silico design and bioengineering to complex biology, powered by our proprietary ProsaRx platforms. Constructive Bio’s groundbreaking programmable biology technology opens new design space for biologics, and together we’re building a programme that could deliver truly novel therapeutics for diseases where current treatments fall short.”
Notes for Editors
About RxCelerate
RxCelerate is an outsourced drug discovery and development company based in Cambridge, UK, and founded in 2013. Known for our focus on innovation and scientific excellence, RxCelerate has a decade-long legacy of successfully delivering bespoke programmes to a global client base, expanding across Europe and the USA.
Our highly talented scientists can deliver both standalone services and fully integrated drug discovery and development programmes, with capabilities spanning in silico design, antibody discovery, medicinal chemistry, bioanalysis, in vitro and preclinical studies, and project management. Clients also benefit from our proprietary platform technologies: RxNfinity™ for rapid in silico screening, the Galaxy® platform for diverse ‘clinic-ready’ antibodies, and ProQuant® for precise bottom-up proteomics.
RxCelerate operates a unique model, offering collaborative strategic thinking to clients to help design and execute every aspect of their research and development plans, turning promising discoveries into potential novel therapeutics.
For more information, please visit www.rxcelerate.com or contact us at [email protected]
About Constructive Bio
At Constructive Bio we rewrite the genome to build the biomolecules of the future. Our unique technology turns living cells into biofactories, creating sustainable new materials and therapeutics. With full control of the genetic sequence and code, we are exploring chemical space previously unreached by natural biology.
Through exclusive access to breakthrough science from the MRC Laboratory of Molecular Biology, based on the research carried out by our founder Professor Jason Chin, Constructive Bio alone has the ability to rewrite entire genomes and incorporate multiple non-canonical amino acids in a single molecule.
Constructive Bio is realising the full scientific and commercial potential of its technologies through its proprietary programmable biology platform. The technology is built on two pillars:
Full genome synthesis: We assemble DNA into genome-scale pieces, stitching and replacing megabases of DNA inside living cells. Through this process, we create entirely new genomes from scratch, writing the genetic blueprint of cells with unprecedented flexibility and precision.
Engineered protein translation: Constructive Bio synthesises proteins with expanded functions by incorporating non-canonical amino acids (ncAAs). Through reprogramming the genetic code of cells and expanding their repertoire of chemical building blocks, our technology creates biofactories for the discovery and manufacturing of novel biopolymers. These molecules have unique properties and diverse applications across science and industry, particularly across pharmaceutical, where they can be used to develop more targeted, effective, and innovative therapeutics.
For more information, please visit constructive.bio or contact us at [email protected].